ÂÜŔňÂŇÂ×

Dr. van den Anker is a pediatric clinical pharmacologist and authority in pediatric and neonatal clinical drug trials. He is actively involved in pediatric clinical pharmacology programs in both the USA (Children’s National Medical Center, Washington, DC and Johns Hopkins University, Baltimore, MD) and Europe (University of Basel Children’s Hospital, Basel, Switzerland and Erasmus Medical Center-Sophia Children’s Hospital in Rotterdam, the Netherlands). Dr. van den Anker was appointed as CMO in 2017 and he will split his time between his research positions in Basel and Washington and supporting ReveraGen as CMO.